賽生藥業(06600.HK)與Tarveda就HSP90-PI3K小分子偶聯藥物訂立獨家許可協議
格隆匯9月16日丨賽生藥業(06600.HK)發佈公吿,2021年9月16日,公司與Tarveda Therapeutics, Inc.(“Tarveda”)訂立合作與許可協議,據此,Tarveda授出獨家許可,准許公司於大中華地區(包括中國內地、中國香港、中國澳門及中國台灣)開發、生產及商業化目前處於臨牀前階段的小分子偶聯藥物產品組合,該組合由磷脂酰肌醇3-激酶(“PI3K”)抑制劑(未披露)有效載荷部分、連接體及熱休克蛋白90(“HSP90”)偶聯部分構成。
根據許可協議及相關條款條件,公司將以現金形式向Tarveda支付預付款,並有權對Tarveda作出股權投資,並於達成各項預先制定的開發、監管批准及商業銷售各關鍵里程碑時另行付款。此外,Tarveda將有資格根據許可產品組合於大中華區的銷售淨額收取特許權使用費。
許可協議基於公司與Tarveda於2020年3月簽訂的有關就PEN-866於大中華區合作的獨家許可協議。公司進一步擴大與Tarveda的合作與戰略伙伴關係,並相信此種更為密切的合作關係將增強公司與Tarveda於臨牀前研究及臨牀開發等方面的優勢互補。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.